DBV Technologies reported $165.7M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
Amarin USD 156.51M 12.95M Sep/2026
BioCryst Pharmaceuticals USD 96.97M 58M Sep/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
DBV Technologies USD 165.7M 9.2M Sep/2026
Galectin Therapeutics USD 25.6M 2.04M Jun/2024
Halozyme Therapeutics USD 1.03B 866.85M Sep/2026
Incyte USD 3.85B 127.8M Sep/2026
Insmed USD 396.56M 148.2M Sep/2026
Ionis Pharmaceuticals USD 296.3M 53.76M Sep/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
PTC Therapeutics USD 508.89M 540.99M Sep/2026
Sarepta Therapeutics USD 472.76M 98.39M Sep/2026
Ultragenyx Pharmaceutical USD 150M 25M Sep/2026
United Therapeutics USD 1.19B 614.3M Sep/2026